Search results for "Neoplastic"

showing 10 items of 2901 documents

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

2010

Background: Drug development traditionally has relied upon the complementary contributions of clinicians and scientists at academic institutions and at pharmaceutical companies. Greater regulatory burdens, increased bureaucratic requirements, restricted reimbursement, and spiralling research and development costs are exerting pressure on the drug development pipeline. The result is a de-emphasis of exploratory research, particularly independent academic research, despite its proven value in identifying new drug targets and developing innovative cancer therapies. Design: An expert panel assembled by the Biotherapy Development Association-a nonprofit international forum for academic and indus…

Oncologymedicine.medical_specialtyacademic research Clinical Trials Directive drug development investigator-initiated trials oncologytargeted therapiesSettore MED/06 - Oncologia MedicaeducationExploratory researchReviewsAntineoplastic AgentsPatient advocacyInternal medicineNeoplasmsmedicineHumanshealth care economics and organizationsReimbursementLicensureGovernmentClinical Trials as Topicbusiness.industryLegislatureHematologyResearch PersonnelClinical trialOncologyDrug developmentbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

The treatment of advanced gastric cancer: current strategies and future perspectives.

2008

Oncologymedicine.medical_specialtybusiness.industryAdvanced stageCancerHematologyAdvanced gastric cancermedicine.diseasePrognosisGastroenterologyOncologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisbusinessStomach cancerForecastingAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Current challenges in metastasis: Disseminated and circulating tumor cells detection

2014

Metastatic dissemination of the primary tumor is responsible for the majority of cancer-related morbidity and mortality. Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in the peripheral blood is associated with early metastatic recurrence in cancer. Circulating tumor cells (CTCs) shed from the site of disease in metastatic or primary tumor that can be recognized and enriched in the peripheral blood of cancer patients. The detection of rare circulating tumor cells (CTC) is an objective of numerous oncologists' researches. Circulating tumor cells have the potential to help to detect cancer recurrence at its earlier stage, determine therapy resistance befo…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCancerGeneral MedicineDiseaseNeoplastic Cells Circulatingmedicine.diseasePrimary tumorMetastasisClinical trialmedicine.anatomical_structureCirculating tumor cellNeoplasmsInternal medicinemedicineHumansImmunology and AllergyBone marrowNeoplasm MetastasisNeoplasm Recurrence LocalStage (cooking)businessHuman Antibodies
researchProduct

Oral vinorelbine may not induce acute pain at the tumor site.

2006

Oncologymedicine.medical_specialtybusiness.industryTreatment outcomeAdministration OralPainVinorelbineVinorelbineVinblastineTumor siteAntineoplastic Agents PhytogenicVinblastineAnesthesiology and Pain MedicineTreatment OutcomeInternal medicineNeoplasmsmedicineHumansNeurology (clinical)businessGeneral NursingAcute painmedicine.drugPain Measurement
researchProduct

MicroRNAs and their role in the malignant transformation of oral leukoplakia: a scoping review

2021

Background MiRNAs are small non-coding RNAs that regulate gene expression at the post-transcriptional level and have been associated with malignant transformation of oral epithelial precursor lesions such as oral leukoplakia. The aim was to perform a scoping review of the contemporary literature about the different roles of miRNAs during the malignant transformation of oral leukoplakia. Material and Methods We conducted a systematic search with the following MeSH terms: ‘oral leukoplakia’, ‘carcinoma in situ’, ‘microRNAs’, ‘mouth neoplasms’ and ‘epithelial–mesenchymal transition’ in PubMed/MEDLINE, EMBASE and SpringerLink. Results Fifteen articles were included for analysis, among which in …

Oncologymedicine.medical_specialtycone-beam computed tomographyMEDLINEReviewMalignant transformationstomatognathic systemOral Cancer and Potentially malignant disordersInternal medicinemicroRNAmedicineHumansProspective StudiesProspective cohort studyGeneral DentistryUNESCO:CIENCIAS MÉDICASsalivary gland calculiMouth neoplasmMesh termbusiness.industryCarcinoma in situmedicine.diseaseobserver variationOral leukoplakiaMicroRNAsstomatognathic diseasesCell Transformation NeoplasticOtorhinolaryngologyMouth NeoplasmsSurgeryLeukoplakia OralbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

2020

MicroRNAs have emerged as new diagnostic and therapeutic biomarkers for breast cancer. Herein, we analysed miR-99a-5p expression levels in primary tumours and plasma of breast cancer patients to evaluate its usefulness as a minimally invasive diagnostic biomarker. MiR-99a-5p expression levels were determined by quantitative real-time PCR in three independent cohorts of patients: (I) Discovery cohort: breast cancer tissues (n = 103) and healthy breast tissues (n = 26)

Oncologymedicine.medical_specialtydiagnosisDown-RegulationBreast NeoplasmsReal-Time Polymerase Chain ReactionArticleCatalysislcsh:ChemistryInorganic Chemistrybreast cancerBreast cancerInternal medicinemicroRNABiomarkers TumorHumansMedicineDiagnostic biomarkerCirculating MicroRNAPhysical and Theoretical Chemistryskin and connective tissue diseaseslcsh:QH301-705.5Molecular BiologyEarly Detection of CancerplasmaSpectroscopyRetrospective StudiesEarly breast cancerPlasma samplesbusiness.industryOrganic ChemistryGeneral MedicineMiddle Agedmedicine.diseaseComputer Science ApplicationsGene Expression Regulation NeoplasticMicroRNAsROC Curvelcsh:Biology (General)lcsh:QD1-999Potential biomarkersCohortbiomarkerBiomarker (medicine)FemalebusinessInternational Journal of Molecular Sciences
researchProduct

Systemic Therapies in Hepatocellular Carcinoma

2009

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors worldwide in the human population. Due to late diagnosis and/or advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefit are available in up to 70% of patients. During the last decades, no effective conventional cytotoxic systemic therapy was available contributing to the dismal prognosis in patients with advanced disease. However, a better knowledge of molecular hepatocarcinogenesis provides today the opportunity for targeted therapy. Positive data from the pivotal phase III SHARP trial assessing the efficacy and safety of the multikinase inhibitor sorafenib broade…

Oncologymedicine.medical_specialtyeducation.field_of_studyCarcinoma HepatocellularCirrhosisbusiness.industryLiver NeoplasmsPopulationGastroenterologyAntineoplastic AgentsGeneral Medicinemedicine.diseasedigestive system diseasesDrug Delivery SystemsLate diagnosisInternal medicineHepatocellular carcinomamedicineHumansIntercellular Signaling Peptides and ProteinsbusinesseducationSignal TransductionDigestive Diseases
researchProduct

Hereditary ovarian cancer.

2008

Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Resistance to standard chemotherapeutic strategies also seems to be due to alterations in the apoptotic pathway of cancer cells. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer. These new target include those acting in the ext…

Oncologymedicine.medical_specialtyendocrine system diseasesColorectal cancerMLH1Germline mutationNeoplastic Syndromes HereditaryInternal medicineGenetic predispositionMedicineHumansGenetic Predisposition to DiseaseGenetic testingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryBRCA mutationHematologymedicine.diseasePrognosisfemale genital diseases and pregnancy complicationsovarian cancerOncologyMSH2FemalebusinessOvarian cancer
researchProduct

Current questions for the treatment of advanced gastric cancer.

2013

Abstract Background Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in advanced gastric cancer. Material and methods Seven questions of special clinical interest have been formulated previously to the literature review. With the aim of answering each of these questions, a specific search of the relevant trials and meta-analyses published or communicated from 1990 to date was performed. Results Patients treated with CT have a survival benef…

Oncologymedicine.medical_specialtymedicine.medical_treatmentAntibodies Monoclonal HumanizedTargeted therapyTrastuzumabStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingMolecular Targeted TherapyRandomized Controlled Trials as TopicPerformance statusbusiness.industryCancerGeneral MedicineTrastuzumabmedicine.diseaseSurgeryOxaliplatinIrinotecanRegimenOncologyDocetaxelbusinessmedicine.drugCancer treatment reviews
researchProduct

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

2007

To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR).Forty-seven women with non-metastatic, non-inflammatory, large or locally advanced breast cancer were included. Tumour uptake of FDG was evaluated before and after the first course of neoadjuvant chemotherapy. Four indices were used: maximal and average SUV without or with correction by body surface area and glycaemia (SUV(max), SUV(avg), SUV(max-BSA-G) and SUV(avg-BSA-G), respectively). The predictive value of reduction in FDG uptake with respect to pCR was studied by logistic regression analysis. Relationships betwe…

Oncologymedicine.medical_specialtymedicine.medical_treatmentPathological responseAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSensitivity and Specificity030218 nuclear medicine & medical imaging18f fdg pet[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicinemedicineHumansRadiology Nuclear Medicine and imagingNeoadjuvant therapyComputingMilieux_MISCELLANEOUSChemotherapymedicine.diagnostic_testbusiness.industryFdg uptakeReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseasePrognosisNeoadjuvant Therapy3. Good healthClinical trialTreatment OutcomePositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyFemaleRadiopharmaceuticalsbusiness
researchProduct